AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+9.46%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.03B
AUM Growth
+$3.03B
(+3.1%)
Cap. Flow
+$76.1M
Cap. Flow
% of AUM
2.51%
Top 10 Holdings %
Top 10 Hldgs %
46.17%
Holding
153
New
22
Increased
19
Reduced
69
Closed
16
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$83M |
| 2 |
KLRS
Kalaris Therapeutics, Inc. Common Stock
KLRS
|
$63.9M |
| 3 |
KE Holdings
BEKE
|
$53.3M |
| 4 |
IGMS
IGM Biosciences
IGMS
|
$50.8M |
| 5 |
iTeos Therapeutics
ITOS
|
$27M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$42.9M |
| 2 |
PayPal
PYPL
|
$34.8M |
| 3 |
Avantor
AVTR
|
$34M |
| 4 |
argenx
ARGX
|
$33M |
| 5 |
Zillow
Z
|
$28.7M |
Sector Composition
| 1 | Healthcare | 78.37% |
| 2 | Consumer Discretionary | 13.95% |
| 3 | Technology | 3.4% |
| 4 | Real Estate | 1.76% |
| 5 | Materials | 1.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
WW
1
DELISTED
WW International
WW
| $280M | 6.79% | 14,818,300 | – | – |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $258M | 6.26% | 900,000 +50,000 | +6% | +$14.3M |
|
|
XLRN
3
DELISTED
Acceleron Pharma Inc.
XLRN
| $158M | 3.82% | 1,400,000 | – | – |
|
4
Alibaba
BABA
$322B
| $125M | 3.03% | 425,000 +52,500 | +14% | +$15.4M |
|
5
BioNTech
BNTX
$24B
| $120M | 2.91% | 1,731,214 -268,786 | -13% | -$18.6M |
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $116M | 2.83% | 800,000 -100,000 | -11% | -$14.6M |
|
7
Generation Bio
GBIO
$40.4M
| $87M | 2.11% | 2,814,191 | – | – |
|
8
Lexicon Pharmaceuticals
LXRX
$400M
| $86.7M | 2.11% | 60,240,864 | – | – |
|
|
9
argenx
ARGX
$43.6B
| $85.1M | 2.07% | 324,200 -125,800 | -28% | -$33M |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $83M | 2.02% | +500,000 | New | +$83M |
|
11
GDS Holdings
GDS
$6.62B
| $81.8M | 1.99% | 1,000,000 -100,000 | -9% | -$8.18M |
|
|
KLRS
12
Kalaris Therapeutics, Inc. Common Stock
KLRS
$76.3M
| $63.9M | 1.55% | +2,323,371 | New | +$63.9M |
|
13
Fate Therapeutics
FATE
$120M
| $60M | 1.46% | 1,500,000 -300,000 | -17% | -$12M |
|
|
14
KE Holdings
BEKE
$20.8B
| $53.3M | 1.29% | +870,000 | New | +$53.3M |
|
|
IGMS
15
DELISTED
IGM Biosciences
IGMS
| $50.8M | 1.23% | +688,910 | New | +$50.8M |
|
16
Black Diamond Therapeutics
BDTX
$157M
| $46M | 1.12% | 1,521,517 -25,000 | -2% | -$756K |
|
|
MORF
17
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $45.2M | 1.1% | 1,651,686 -17,500 | -1% | -$478K |
|
18
Scholar Rock
SRRK
$3.14B
| $44.1M | 1.07% | 2,495,140 -28,900 | -1% | -$511K |
|
19
Schrodinger
SDGR
$1.44B
| $42.6M | 1.04% | 897,445 | – | – |
|
20
Amicus Therapeutics
FOLD
$2.34B
| $42.4M | 1.03% | 3,000,000 -500,000 | -14% | -$7.06M |
|
21
TG Therapeutics
TGTX
$4.65B
| $40.1M | 0.97% | 1,500,000 -250,000 | -14% | -$6.69M |
|
|
IMAB
22
I-MAB
IMAB
$340M
| $34.1M | 0.83% | 725,000 +401,000 | +124% | +$18.9M |
|
23
NovaGold Resources
NG
$2.78B
| $30.9M | 0.75% | 2,600,000 | – | – |
|
|
DCPH
24
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $30.8M | 0.75% | 600,000 -50,000 | -8% | -$2.57M |
|
25
Gossamer Bio
GOSS
$562M
| $29.3M | 0.71% | 2,358,968 -300,000 | -11% | -$3.72M |
|